UNSPSC 51433601: Ketanserin

This classification denotes a serotonin antagonist with the molecular formula C22H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97F9DE4CT4, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)- but generally known as ketanserin, which bears US NIH Compound Identifier 3822. European Medicines Agency schedules Ketanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08366MIG. The term KETANSERIN is an International Non-Proprietary Name.

UNSPSC 51433601 Ketanserin, a Commodity code, designates individual pharmaceutical products procured by state and local government health care and emergency response programs. Recent solicitations under this code show state and local entities buying advanced life support medications, generic pharmaceuticals, and over-the-counter products for distribution through emergency medical services, health and human services agencies, and multistate cooperative purchasing networks. The City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of issuing bodies — municipal emergency services, state health agencies, and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. Work solicited includes supply of specific medication line items with strict expiration-date and quality-assurance requirements, direct-to-manufacturer contracting arrangements, and generic pharmaceuticals distributed through authorized wholesalers with compliance to cGMP, FDA standards, and Drug Supply Chain Security Act requirements.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued an Invitation for Bid (IFB) in April 2026 for Advanced Life Support Medications (Solicitation 26P00188, response due April 8, 2026) to supply Tampa Fire Rescue with specific quantities of Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials at an estimated contract value of $40,000, with a 5 percent bid discount available to Small Local Business Enterprises. The Texas Health and Human Services Commission posted a Request for Information (RFI) in early April 2026 to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, with no dollar value or binding timeline attached. The Minnesota Department of Administration issued an RFP through MMCAP in January 2026 (response due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon through three authorized wholesalers, with evaluation weighted heavily on price competitiveness (75 percent), contract term of two years, and a 3 percent administrative fee on purchases.